scholarly journals Biomimetic nanoscale metal–organic framework harnesses hypoxia for effective cancer radiotherapy and immunotherapy

2020 ◽  
Vol 11 (29) ◽  
pp. 7641-7653 ◽  
Author(s):  
Kaiyuan Ni ◽  
Guangxu Lan ◽  
Yang Song ◽  
Ziyang Hao ◽  
Wenbin Lin
Keyword(s):  
Cancer Treatment ◽  
Immune Checkpoint ◽  
Metal Organic Framework ◽  
Tumor Hypoxia ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Cancer Radiotherapy ◽  
Metal Organic ◽  
Synergistic Combination ◽  
Organic Framework

Biomimetic Hf-DBP-Fe harnesses tumor hypoxia for cancer treatment via RT-RDT and CDT as well as synergistic combination with immune checkpoint blockade.

scholarly journals Immune Checkpoint Blockade: The New Frontier in Cancer Treatment

2018 ◽  
Vol 13 (1) ◽  
pp. 1-20 ◽  
Author(s):  
Jeffrey M. Clarke ◽  
Daniel J. George ◽  
Stacey Lisi ◽  
April K. S. Salama
Keyword(s):  
Cancer Treatment ◽  
Immune Checkpoint ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
New Frontier

Folic acid-modified metal-organic framework carries CPT and DOX for cancer treatment

2021 ◽  
pp. 122803
Author(s):  
Bao-Xuan Xie ◽  
Wen Shu ◽  
Hai-Shuang Wang ◽  
Li Chen ◽  
Jin Xu ◽  
...  
Keyword(s):  
Folic Acid ◽  
Cancer Treatment ◽  
Metal Organic Framework ◽  
Metal Organic ◽  
Organic Framework

scholarly journals Metal-Organic Framework Nanoparticle-Based Biomineralization: A New Strategy toward Cancer Treatment

Theranostics ◽  
2019 ◽  
Vol 9 (11) ◽  
pp. 3134-3149 ◽  
Author(s):  
Chengchao Chu ◽  
Min Su ◽  
Jing Zhu ◽  
Dongsheng Li ◽  
Hongwei Cheng ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Metal Organic Framework ◽  
New Strategy ◽  
Metal Organic ◽  
Organic Framework

scholarly journals Dynamic Collaborations for the Development of Immune Checkpoint Blockade Agents

2021 ◽  
Vol 11 (6) ◽  
pp. 460
Author(s):  
Arisa Djurian ◽  
Tomohiro Makino ◽  
Yeongjoo Lim ◽  
Shintaro Sengoku ◽  
Kota Kodama
Keyword(s):  
Cancer Treatment ◽  
Immune Checkpoint ◽  
Success Factors ◽  
Interorganizational Collaboration ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Drug Candidates ◽  
Innovative Drugs ◽  
Product Sales ◽  
Checkpoint Blockade Agents

We studied the overview of drug discovery and development to understand the recent trends and potential success factors of interorganizational collaboration by reviewing 1204 transactions performed until 2019 for 107 anticancer drugs approved by the US Food and Drug Administration (FDA) from 1999 to 2018. Immune checkpoint blockade was found to be a significantly active area in interorganizational transactions, especially the number of alliances, compared with other mechanisms of action of small molecules and biologics for cancer treatment. Furthermore, the analysis of pembrolizumab and nivolumab showed that the number of approved indications for these two drugs has been rapidly expanding since their first approval in 2014. Examination of the acquisitions and alliances regarding pembrolizumab and nivolumab showed that many combination partners were developed by US-based biotechnology or start-up companies, the majority of which were biologics. These findings suggest that immune checkpoint blockade is a paradigm for cancer treatment, resulting in huge product sales and continuous indication expansion. Additionally, interorganizational collaboration, especially trial collaboration, is a strategic approach for the development of immune checkpoint blockade agents. The translation of these empirical practices to new drug candidates is expected for the research and development of innovative drugs in the future.

scholarly journals Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an “Innocent Bystander”

Toxins ◽  
2014 ◽  
Vol 6 (3) ◽  
pp. 914-933 ◽  
Author(s):  
Lucia Gelao ◽  
Carmen Criscitiello ◽  
Angela Esposito ◽  
Aron Goldhirsch ◽  
Giuseppe Curigliano
Keyword(s):  
Cancer Treatment ◽  
Immune Checkpoint ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Innocent Bystander

Biomarkers of response to immune checkpoint blockade in cancer treatment

2018 ◽  
Vol 130 ◽  
pp. 108-120 ◽  
Author(s):  
Takeo Fujii ◽  
Aung Naing ◽  
Christian Rolfo ◽  
Joud Hajjar
Keyword(s):  
Cancer Treatment ◽  
Immune Checkpoint ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade
Sign in / Sign up

Export Citation Format

Share Document